ovarian cancer

ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
Clinical Trials Arena
Immunogen
Elahere
clinical trials
platinum-resistant ovarian cancer
ovarian cancer
Flag link:
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
Clinical Trials Arena
Immunogen
clinical trial
ovarian cancer
platinum-resistant ovarian cancer
Elahere
Flag link:
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Flag link:
GSK told to pay higher royalties to AZ on Zejula sales
GSK told to pay higher royalties to AZ on Zejula sales
Pharmaphorum
GSK
AstraZeneca
ovarian cancer
Zejula
legal
UK
Flag link:
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
Endpoints
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
clinical trials
Flag link:
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
bankruptcy
Flag link:
Cyteir lays off 70% of workforce after further narrowing cancer drug goals
Cyteir lays off 70% of workforce after further narrowing cancer drug goals
Fierce Biotech
Cyteir Therapeutics
layoffs
CYT-0851
ovarian cancer
Flag link:
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Endpoints
Sutro BioPharma
clinical trials
antibody-drug conjugate
ovarian cancer
luveltamab tazevibulin
Flag link:
OncoC4 doses first participant in ovarian cancer therapy trial
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Clovis Oncology
Rubraca
ovarian cancer
FDA
Flag link:
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
FDA bestows accelerated approval on ImmunoGen's ovarian cancer drug, with confirmatory answer coming soon
Endpoints
Immunogen
FDA
ovarian cancer
mirvetuximab soravtansine
Flag link:
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request
BioSpace
GSK
ovarian cancer
Zejula
PARP inhibitors
FDA
Flag link:
ImmunoGen commercial chief to withdraw before drug launch
ImmunoGen commercial chief to withdraw before drug launch
Medical Marketing and Media
Immunogen
mirvetuximab soravtansine
ovarian cancer
Flag link:
A startup plans an IPO to give a shelved Lilly drug another shot
A startup plans an IPO to give a shelved Lilly drug another shot
BioPharma Dive
Acrivon Therapeutics
IPOs
Eli Lilly
prexasertib
ovarian cancer
endometrial cancer
bladder cancer
precision medicine
Flag link:
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
prostate cancer
Flag link:
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
Fierce Pharma
AstraZeneca
Merck
Lynparza
ovarian cancer
Flag link:
Celsion’s Phase I/II ovarian cancer trial completes subject enrolment
Celsion’s Phase I/II ovarian cancer trial completes subject enrolment
Clinical Trials Arena
Celsion
ovarian cancer
GEN-1
clinical trials
Flag link:
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:

Pages